Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), bought 20,000 shares at $0.95 ($18K) on 2022-05-31, disclosed to the SEC on 2022-06-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.87 | 78 | $68 | 0.4% |
| 2 | $0.88 | 2,900 | $3K | 13.9% |
| 3 | $0.89 | 200 | $178 | 1.0% |
| 4 | $0.90 | 1,000 | $900 | 4.9% |
| 5 | $0.92 | 7,995 | $7K | 39.9% |
| 6 | $0.93 | 60 |
| $56 |
| 0.3% |
| 7 | $0.94 | 6,539 | $6K | 33.4% |
| 8 | $0.95 | 1,228 | $1K | 6.3% |
| Total | $0.92 avg | 20,000 | $18K | 100% |
| Filing → |
| RSLS | SELL | 2023-07-19 | $156 | — | Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |